Carboplatin + Cisplatin + Durvalumab + Etoposide
Phase 2Withdrawn 3 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Lung Small Cell Carcinoma
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Trial Timeline
Oct 19, 2023 → Dec 31, 2024
NCT ID
NCT05161533About Carboplatin + Cisplatin + Durvalumab + Etoposide
Carboplatin + Cisplatin + Durvalumab + Etoposide is a phase 2 stage product being developed by AstraZeneca for Extensive Stage Lung Small Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05161533. Target conditions include Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8.
What happened to similar drugs?
0 of 11 similar drugs in Extensive Stage Lung Small Cell Carcinoma were approved
Approved (0) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05161533 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Extensive Stage Lung Small Cell Carcinoma